Safety and efficacy of eplerenone in patients at high risk for. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. Eplerenone is approved for treating heart failure after myocardial infarction in 72 countries. Baseline characteristics of the patients in the jemphasishf study kaplan meier plots.
Pdf spironolactone for heart failure with preserved. Moreover, the cumulative event rate of death during 1 year in the placebo group in the jemphasishf study 0. Clinical benefits of eplerenone in patients with systolic. Mineralocorticoid receptor antagonists mras in heart failure survival total mortality 30% rr, p trial or 25 mg every 2nd day to 50 mg daily depending on gfr in class ii hf with lvef. Background mineralocorticoid receptor antagonists mras have been shown to reduce morbidity and mortality in patients with hf with reduced ejection fraction hfref and in a subset of patients with hf. The emphasishf trial showed that eplerenone is safe, and can improve survival and prevent readmission when initiated soon after a hospitalisation for hf, in patients with acute coronary. Eplerenone might be effective in reducing the incidence of these adverse clinical outcomes during this period. Hospitalizations for heart failure and for any cause were also reduced with eplerenone. To uninstall your trial version on a windows device, close any open adobe software on your computer, open the windows control panel and doubleclick programs and features. Effect of enalapril on survival in patients with reduced. All analyses were performed or replicated independently at the london school of hygiene and tropical medicine tim collier. Pulmonary artery pressureguided management of patients. In this trial, 2737 patients with heart failure and lv systolic dysfunction were given eplerenone or placebo in addition to recommended therapy. Download limit exceeded you have exceeded your daily download allowance.
To demonstrate in a large and simple clinical trialapproach that digitoxin target serum concentrations preferably 8 18 ngml 10. The purpose of the emphasis hf trial was to explore the effects of adding eplerenone, a type of mineralocorticoid antagonist, to evidencebased therapy in patients with systolic heart failure and only mild symptoms i. Methods and results results from the emphasishf trial were used to develop a discreteevent simulation model estimating lifetime direct costs and effects life years and qualityadjusted life. Results from the emphasishf eplerenone in mild patients. Objectives this study sought to assess the effect of mra treatment vs. Publications home of jama and the specialty journals of. Emphasis hff zannad inserm, nancy university, franceamerican heart association 2010 scientific sessions background. Costeffectiveness of eplerenone in nyha class ii chronic. The eplerenone in mild patients hospitalization and survival study in heart failure emphasishf trial compared eplerenone with placebo in. The overall results of this trial are consistent with the results of consensus and an overview of other small trials of angiotensinconvertingenzyme inhibitors in congestive heart failure. Spironolactone for heart failure with preserved ejection fraction article pdf available in new england journal of medicine 37015.
Eplerenone in patients with systolic heart failure and. Aldosterone blockadewith spironolactone or the newer more selective eplerenonehas already shown benefits in class 34 hf and in postmi patients with hf this study examined eplerenone in patients with mild hf. Novartis participated in the design and conduct of the paradigmhf trial. After myocardial infarction complicated by heart failure or diabetes, eplerenone compared to placebo significantly decreases aminoterminal propeptide of type iii procollagen. Eplerenone in mild patients hospitalization and survival study in heart failure study. Helmut drexler, who was a member of the emphasis hf executive committee. The purpose of this study was to analyze the incidence of new atrial fibrillation or flutter aff in the emphasishf eplerenone in. Eplerenone in patients with systolic heart failure and mild symptoms. Effect of neprilysin inhibition on renal function in. Additionally, the trial prospectively assessed changes in renal function over a followup period of up to 44 months, and, thus, the study allowed for an assessment of the effects of neprilysin. Importance hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Eplerenone in patients with systolic heart failure and mild. In emphasishf, the mra eplerenone, or placebo, was added to.
Pdf doubleblind, randomized, placebocontrolled trial. Congestive heart failure update and management and. Emphasishff zannad inserm, nancy university, franceamerican heart association 2010 scientific sessions background. Clinical benefits of eplerenone in patients with systolic heart failure.
The article presents the key safety and efficacy results of the trial with specific emphasis on the clinical implications of these findings. Aldosterone antagonists in mild heart failure harsha nagarajarao june, 2012 2. Zannad f1, mcmurray jj, krum h, van veldhuisen dj, swedberg k, shi h, vincent j, pocock sj, pitt b. Mineralocorticoid receptor antagonists, blood pressure. Doubleblind, randomized, placebocontrolled trial evaluating the. There is a considerable knowledge gap regarding neurohormonal blockade in various hf entities. The emphasishf trial compared eplerenone with placebo. In the emphasishf study, a largescale randomized clinical trial involving 2,737 patients with hfref and. Background despite increased use of guidelinedirected medical therapy gdmt, some patients with heart failure and reduced ejection fraction hfref remain at high risk for hospitalization. Mineralocorticoid receptor antagonists mras reduce the risk of atrial fibrillation af in patients with heart failure hf and a reduced ejection fraction. The emphasishf eplerenone in mild patients hospitalization and survival study in heart failure trial was an eventdriven, doubleblind, placebocontrolled trial with a composite. The paradigmhf trial was funded by novartis pharmaceuticals. The purpose of the emphasishf trial was to explore the effects of adding eplerenone, a type of mineralocorticoid antagonist, to evidencebased therapy in patients with systolic heart failure and only.
1460 737 1494 851 681 464 809 400 759 970 1143 1006 882 135 701 1511 704 199 1083 351 741 211 1372 1379 1179 677 251 157 1468 140 1123 912 963 151 1498 1449 1078 145 648 33